Document series
Trial abstracts — page 2
700 structured trial abstracts. Each is one document in five parts: abstract, design and population, results, certainty assessment and citing documents.
Showing 0 records on this page
Trial records
700 documents · page 2 of 30
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| SUMMIT | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 731 | 2024 | Moderate |
| SURMOUNT-4 | Tirzepatide | Phase 3 | Reported | Randomised withdrawal | 670 | 2024 | High |
| SURMOUNT-OSA-1 | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | High |
| SURMOUNT-OSA-2 | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | High |
| SURVO-PH2-MASH | Survodutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 295 | 2024 | Low |
| SURVO-PH2-OBESITY | Survodutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 387 | 2024 | Moderate |
| SYNERGY-NASH | Tirzepatide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 190 | 2024 | Low |
| CAGRI-SEMA-PH2-T2D | CagriSema (cagrilintide with semaglutide) | Phase 2 | Reported | Randomised, double-blind, active-controlled | 92 | 2023 | Low |
| DANU-PH2B-OBESITY | Danuglipron | Phase 2b | Programme discontinued | Randomised, double-blind, placebo-controlled | 605 | 2023 | Not rated |
| DANU-PH2B-T2D | Danuglipron | Phase 2b | Programme discontinued | Randomised, double-blind, placebo-controlled | 411 | 2023 | Not rated |
| MAZ-PH2-OBESITY | Mazdutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 248 | 2023 | Moderate |
| OASIS-1 | Semaglutide, oral | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 667 | 2023 | Moderate |
| ORFO-PH2-OBESITY | Orforglipron | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 272 | 2023 | Moderate |
| ORFO-PH2-T2D | Orforglipron | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 383 | 2023 | Moderate |
| RETA-PH2-OBESITY | Retatrutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 338 | 2023 | Moderate |
| RETA-PH2-T2D | Retatrutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 281 | 2023 | Moderate |
| SELECT | Semaglutide | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 17,604 | 2023 | High |
| STEP-HFpEF | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 529 | 2023 | Moderate |
| SURMOUNT-2 | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 938 | 2023 | High |
| SURMOUNT-3 | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 806 | 2023 | High |
| CELIAC-PH3-CEDLARA | Larazotide acetate | Phase 3 | Terminated | Randomised, double-blind, placebo-controlled | — | 2022 | Not rated |
| MMPOWER-3 | SS-31 (elamipretide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 218 | 2022 | Moderate |
| STEP-5 | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 304 | 2022 | High |
| STEP-8 | Semaglutide | Phase 3 | Reported | Randomised, double-blind, active-controlled | 338 | 2022 | High |
page 2 of 30